Cancers that overexpress HER2 have been linked with worse prognosis when compared with matched HER2 non-amplified ones, including a higher mortality rate in early stages of the disease, reduced relapse time, and a higher incidence of metastases [50,51]. The gene discussed is ERBB2; the disease is cancer.